Department of Molecular Biology, University of Salzburg, Salzburg, Austria.
Prog Mol Biol Transl Sci. 2011;99:51-103. doi: 10.1016/B978-0-12-385504-6.00002-6.
Blood hemostasis is accomplished by a complex network of (anti-)coagulatory and fibrinolytic processes. These physiological processes are implemented by the assembly of multiprotein complexes involving both humoral and cellular components. Coagulation factor X, and particularly, factor IX, exemplify the dramatic enhancement that is obtained by the synergistic interaction of cell surface, inorganic and protein cofactors, protease, and substrate. With a focus on structure-function relationship, we review the current knowledge of activity modulation principles in the coagulation proteases factors IX and X and indicate future challenges for hemostasis research. This chapter is organized by describing the principles of hierarchical activation of blood coagulation proteases, including endogenous and exogenous protease activators, cofactor binding, substrate specificities, and protein inhibitors. We conclude by outlining pharmaceutical opportunities for unmet needs in hemophilia and thrombosis.
血液止血是通过一系列复杂的(抗)凝血和纤维蛋白溶解过程来实现的。这些生理过程是通过涉及体液和细胞成分的多种蛋白质复合物的组装来实现的。凝血因子 X,特别是因子 IX,是通过细胞表面、无机和蛋白质辅因子、蛋白酶和底物的协同相互作用获得的显著增强的典型例子。本文重点介绍了结构-功能关系,综述了凝血蛋白酶因子 IX 和 X 活性调节原理的最新知识,并指出了止血研究的未来挑战。这一章的组织方式是通过描述血液凝血蛋白酶的级联激活原理来描述的,包括内源性和外源性蛋白酶激活剂、辅因子结合、底物特异性和蛋白质抑制剂。最后,我们概述了在血友病和血栓形成中未满足的药物需求的机会。